Nuvectis Pharma Statistics

Total Valuation

Nuvectis Pharma has a market cap or net worth of $192.15 million. The enterprise value is $162.29 million.

Market Cap	192.15M
Enterprise Value	162.29M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, before market open.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Nuvectis Pharma has 23.63 million shares outstanding. The number of shares has increased by 12.13% in one year.

Current Share Class	23.63M
Shares Outstanding	23.63M
Shares Change (YoY)	+12.13%
Shares Change (QoQ)	+12.27%
Owned by Insiders (%)	45.72%
Owned by Institutions (%)	9.92%
Float	12.83M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	9.17
P/TBV Ratio	9.17
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.28

Current Ratio	3.28
Quick Ratio	3.25
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -115.28% and return on invested capital (ROIC) is -75.12%.

Return on Equity (ROE)	-115.28%
Return on Assets (ROA)	-52.69%
Return on Invested Capital (ROIC)	-75.12%
Return on Capital Employed (ROCE)	-100.31%
Revenue Per Employee	n/a
Profits Per Employee	-$1.55M
Employee Count	13
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +25.58% in the last 52 weeks. The beta is -0.16, so Nuvectis Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.16
52-Week Price Change	+25.58%
50-Day Moving Average	9.26
200-Day Moving Average	7.39
Relative Strength Index (RSI)	37.24
Average Volume (20 Days)	97,487

Short Selling Information

The latest short interest is 2.11 million, so 8.93% of the outstanding shares have been sold short.

Short Interest	2.11M
Short Previous Month	2.10M
Short % of Shares Out	8.93%
Short % of Float	16.44%
Short Ratio (days to cover)	16.06

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-21.02M
Pretax Income	-21.10M
Net Income	-20.16M
EBITDA	n/a
EBIT	-21.02M
Earnings Per Share (EPS)	-$1.12

Full Income Statement

Balance Sheet

The company has $29.86 million in cash and n/a in debt, giving a net cash position of $29.86 million or $1.26 per share.

Cash & Cash Equivalents	29.86M
Total Debt	n/a
Net Cash	29.86M
Net Cash Per Share	$1.26
Equity (Book Value)	20.95M
Book Value Per Share	0.89
Working Capital	20.95M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-12.06M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nuvectis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.13%
Shareholder Yield	-12.13%
Earnings Yield	-10.49%
FCF Yield	n/a

Analyst Forecast

The average price target for Nuvectis Pharma is $17.00, which is 109.88% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.00
Price Target Difference	109.88%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1